OPKO Health, Inc. Proceeds from Issuance of Senior Long-term Debt
OPKO Health, Inc. (OPK) reported Proceeds from Issuance of Senior Long-term Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt · last filed 2026-02-26
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for the quarter ending 2025-12-31 was $0.00.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for the quarter ending 2024-12-31 was $0.00.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for the quarter ending 2023-12-31 was $0.00.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for the quarter ending 2018-09-30 was $0.00.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for fiscal 2024 was $250.00M.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for fiscal 2023 was $0.00.
- OPKO Health, Inc. proceeds from issuance of senior long-term debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Senior Long-term Debt 3 month | Proceeds from Issuance of Senior Long-term Debt 6 month | Proceeds from Issuance of Senior Long-term Debt 9 month | Proceeds from Issuance of Senior Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $250.00M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $250.00M 10-Q · filed 2025-10-29 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $55.00M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $55.00M 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $55.00M 10-Q · filed 2018-05-08 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |